Clinical Trial

Vibegron for ENergy Thinking and Resilience in Aging

Study acronym: VENTURA
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-15; most recent amendment 2026-02-20.
Trial Details
NCT Number NCT06987383
Lead Sponsor Wake Forest University Health Sciences
Collaborators: National Institute on Aging (NIA)
Conditions Obesity
Enrollment 40 participants
Start Date 2026-09
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-04